Verruca Vulgaris Clinical Trial
Official title:
Using a Cold Atmospheric Plasma Device to Treat Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients
This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum. The treatment device in this study generates cold atmospheric plasma (gaseous ionized molecules) to rid the virus from the body. Based on the successes of previous dermatologic studies, FE-DBD is being tested for this study to treat warts and molluscum. Patients will be enrolled to test the efficacy and safety of this device. The duration of the study is 4-12 weeks depending on treatment clearance. The number of lesions will be chosen by the dermatologist. Patients will receive standard of care therapy and/or NTAP depending on the number of lesions.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05937672 -
Cold Atmospheric Plasma Device Extension Study
|
Phase 3 | |
Completed |
NCT00328991 -
Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts
|
N/A | |
Recruiting |
NCT05409365 -
Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris
|
||
Completed |
NCT03487549 -
Cantharidin and Occlusion in Verruca Epithelium
|
Phase 2 | |
Completed |
NCT01084824 -
A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin
|
N/A | |
Terminated |
NCT01609530 -
Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy
|
N/A | |
Recruiting |
NCT04620785 -
Photodynamic Therapy in Treatment of Verrucae
|
N/A | |
Completed |
NCT04793529 -
Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study
|
N/A | |
Recruiting |
NCT05799157 -
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
|
Phase 2 | |
Completed |
NCT02748902 -
Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.
|
Phase 1 | |
Completed |
NCT02483455 -
ALC-919 For The Treatment Of Common Warts
|
Phase 2 |